Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02807051 · ClinicalTrials.gov registry record · Phase 1

To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects

A Phase 1 study, sponsored by CTI BioPharma.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target

NCT02807051: Completed Phase 1 study, sponsored by CTI BioPharma.

NCT02807051 is a Phase 1 study that has completed, run by CTI BioPharma. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02807051, a Phase 1 study, has completed, sponsored by CTI BioPharma.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target

Study Summary

This will be an open-label, single-center, crossover, one-way, drug-interaction study to evaluate the effect of 500 mg clarithromycin BID (dosed to steady state) on the PK of a single 400-mg dose of pacritinib in healthy male and female subjects.

Primary Outcome

To estimate ratios of geometric mean values and the corresponding 90% confidence intervals

Interventions

  • DRUG Pacritinib
  • DRUG Clarithromycin
  • DRUG Pacritinib and Clarithromycin

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2014-09
Est. Completion 2014-10
Phase Phase 1
CTI BioPharma

28 total trials

What the finished NCT02807051 record still lists

NCT02807051 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).

The record links to 0 conditions, and to 3 interventions - of which Pacritinib is the first listed.

NCT02807051 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02807051 about?

NCT02807051 is a clinical study titled "To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects". This will be an open-label, single-center, crossover, one-way, drug-interaction study to evaluate the effect of 500 mg clarithromycin BID (dosed to steady state) on the PK of a single 400-mg dose of pacritinib in healthy male and female subjects.

What is the current status of trial NCT02807051?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2014-09. Estimated completion is 2014-10.

What interventions are being tested in trial NCT02807051?

The interventions under investigation include: Pacritinib (DRUG), Clarithromycin (DRUG), Pacritinib and Clarithromycin (DRUG).

Who is sponsoring clinical trial NCT02807051?

This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02807051's enrollment target sits among peer trials

20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02807051, the US trial registry maintained by the National Library of Medicine. NCT02807051 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.